|
Member
|
|
Join Date: Sep 2006
Posts: 782
|
|
Member
Join Date: Sep 2006
Posts: 782
|
Bioavailability of L-DOPA from HP-200 : a formulation of seed powder of Mucuna pruriens (Bak) : a pharmacokinetic and pharmacodynamic study
Auteur(s) / Author(s)
MAHAJANI S. S. (1) ; DOSHI V. J. ; PARIKH K. M. (1) ; MANYAM B. V. ;
Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)
(1) Divisions of Pharmacology, The Zandu Pharmaceutical Works Ltd., Bombay, INDE
Résumé / Abstract
HP-200, a formulation made from the seed powder of Mucuna pruriens, contains among other constituents, about 4% L-DOPA.
After five normal human volunteers were each given a single oral dose of 30 g of HP-200, plasma samples were obtained at 0, 20, 40, 60, 90, 120, 180, 240 and 360 min for assay of L-DOPA by HPLC technique using electrochemical detection. The supine systolic and diastolic blood pressures were recorded at each sampling time.
The results indicate that on oral administration, L-DOPA was absorbed from HP-200 with plasma peak levels (C[max]=1.56±0.163 μg/mL) achieved at T[max]=83±16.09 min. The plasma half life was 102±2 min and the auc was determined as 6.508±0.421 μg/h/mL.
The pharmacokinetic profile of HP-200 exhibited characteristics similar to formulations of synthetic L-DOPA, except for the lack of a sharp peak. HP-200, a new herbal formulation, appears to be suitable for the treatment of Parkinson's disease.
Revue / Journal Title
PTR. Phytotherapy research (PTR, Phytother. res.) ISSN 0951-418X
Source / Source
1996, vol. 10, no3, pp. 254-256 (7 ref.)
|